The psychology-based digital healthcare platform Noom announced this week that it's now offering off-brand weight loss drugs starting at $149. Roche (RHHBY) stock took a hit early this week after a conference poster noted side effects patients experienced during an early-stage trial of its experimental weight loss drug. And Eli Lilly's experimental weekly insulin worked just as well as daily doses, however, a clinical trial also found that the drug carried a higher risk of severe low blood sugar for type 1 diabetes patients.

Check out those stories and more pharmaceutical news highlights from this week.